Lumosa Therapeutics Co., Ltd. (TPEX: 6535)
Taiwan
· Delayed Price · Currency is TWD 196.50
+5.50 (2.88%)
Dec 20, 2024, 1:30 PM CST
Lumosa Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 37.82 | 56.92 | 26.64 | 17.36 | 21.65 | 172.04 | Upgrade
|
| Revenue Growth (YoY) | -28.38% | 113.63% | 53.45% | -19.81% | -87.42% | 183.83% | Upgrade
|
| Cost of Revenue | 13.96 | 15.44 | 12.08 | 7.47 | 8.49 | 28.64 | Upgrade
|
| Gross Profit | 23.85 | 41.48 | 14.56 | 9.89 | 13.16 | 143.4 | Upgrade
|
| Selling, General & Admin | 54.46 | 47.8 | 40.02 | 34.12 | 37.67 | 55.55 | Upgrade
|
| Research & Development | 318.62 | 369.3 | 280.46 | 406.05 | 317.04 | 237.82 | Upgrade
|
| Operating Expenses | 373.23 | 417.26 | 320.48 | 440.17 | 354.71 | 293.37 | Upgrade
|
| Operating Income | -349.38 | -375.78 | -305.92 | -430.28 | -341.56 | -149.96 | Upgrade
|
| Interest Expense | -0.15 | -0.05 | -0.15 | -0.26 | -0.15 | -0.27 | Upgrade
|
| Interest & Investment Income | 12.81 | 18.49 | 5.84 | 3.46 | 3.41 | 7.26 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.98 | -4.21 | 11.02 | -3.73 | -8.61 | -2.61 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.16 | 2.76 | 2.11 | 1.67 | -0.21 | -126.81 | Upgrade
|
| EBT Excluding Unusual Items | -338.53 | -358.79 | -287.1 | -429.14 | -347.11 | -272.39 | Upgrade
|
| Impairment of Goodwill | - | - | - | -78.49 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -53.92 | 119.08 | -217.4 | 627.61 | 24.5 | 46.15 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | -0 | Upgrade
|
| Asset Writedown | -10.37 | -10.37 | - | -24.03 | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.05 | - | 0.05 | - | Upgrade
|
| Pretax Income | -402.82 | -250.09 | -504.45 | 95.95 | -322.56 | -226.25 | Upgrade
|
| Income Tax Expense | - | 0.25 | 0.04 | - | - | 14.69 | Upgrade
|
| Earnings From Continuing Operations | -402.82 | -250.33 | -504.48 | 95.95 | -322.56 | -240.94 | Upgrade
|
| Minority Interest in Earnings | 14.03 | 12.29 | 9.82 | - | - | - | Upgrade
|
| Net Income | -388.8 | -238.04 | -494.66 | 95.95 | -322.56 | -240.94 | Upgrade
|
| Net Income to Common | -388.8 | -238.04 | -494.66 | 95.95 | -322.56 | -240.94 | Upgrade
|
| Shares Outstanding (Basic) | 162 | 162 | 162 | 151 | 121 | 117 | Upgrade
|
| Shares Outstanding (Diluted) | 162 | 162 | 162 | 151 | 121 | 117 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.03% | 7.61% | 24.92% | 3.01% | 18.59% | Upgrade
|
| EPS (Basic) | -2.39 | -1.47 | -3.05 | 0.64 | -2.67 | -2.05 | Upgrade
|
| EPS (Diluted) | -2.40 | -1.47 | -3.05 | 0.64 | -2.67 | -2.05 | Upgrade
|
| Free Cash Flow | -273.46 | -342.53 | -302.74 | -452.69 | -129.79 | -379.52 | Upgrade
|
| Free Cash Flow Per Share | -1.68 | -2.11 | -1.86 | -3.00 | -1.07 | -3.24 | Upgrade
|
| Gross Margin | 63.08% | 72.88% | 54.65% | 56.96% | 60.77% | 83.35% | Upgrade
|
| Operating Margin | -923.92% | -660.23% | -1148.26% | -2478.27% | -1577.55% | -87.17% | Upgrade
|
| Profit Margin | -1028.15% | -418.23% | -1856.70% | 552.62% | -1489.83% | -140.04% | Upgrade
|
| Free Cash Flow Margin | -723.16% | -601.81% | -1136.33% | -2607.34% | -599.47% | -220.59% | Upgrade
|
| EBITDA | -341.21 | -356.93 | -288.66 | -403.81 | -312.71 | -117.43 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -68.26% | Upgrade
|
| D&A For EBITDA | 8.17 | 18.85 | 17.26 | 26.47 | 28.84 | 32.53 | Upgrade
|
| EBIT | -349.38 | -375.78 | -305.92 | -430.28 | -341.56 | -149.96 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -87.17% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.